Biosynth Develops New Microbial Enzymes for Eco-friendly Consumer Products
Biosynth, which acquired EUCODIS Bioscience in 2022, has taken over the helm in developing new microbial enzymes for generating eco-friendly and innovative consumer products, such as detergents, textiles and cosmetics in collaboration with its partners of the FuturEnzyme consortium.
FuturEnzyme has received total funding of approximately 6 Million Euros from the Horizon 2020 framework program, which commenced in June 2021.
New microbial enzymes for eco-friendly consumer products
Consumer products like textiles, detergents and cosmetics can be ecologically harmful by releasing chemical compounds into the environment during production, use, and disposal, and thereby impact our CO2 emissions. One potential way to diminish the hazards caused by consumer goods is to replace the chemical reagents used in industrial processes with novel enzymes to manufacture these products. The use of new and improved enzymes in cosmetic ingredients, liquid-based detergents, and in textile processing could reduce CO2 emissions by approximately 42 million tons per year.
Notwithstanding the fact, that enzymes covering these activities already exist on the market, very few consumer products contain enzymes as these existing enzymes are often expensive or show low performance.
Dr. Jan Modregger, MBA, Head of Research and Development at EUCODIS Bioscience, which is now operating under the Biosynth brand highlighted:
“Enzymes that meet the consumer demands for high performance and stability, and at the same time are environmental friendly and cost-efficient need to be developed using cutting-edge technologies. Developing such innovative enzymes is one of the major goals of Eucodis in this FuturEnzyme project.”
About the FuturEnzyme project
The FuturEnzyme project is led by a team of researchers around Manuel Ferrer from the Spanish National Research Council (CSIC), and the consortium consists of 16 European academic and industrial partners from Spain, Germany, Italy, Austria, Portugal, the United Kingdom, and Switzerland. Biosynth participates in all the following stages, the characterization of the candidate enzymes, their improvement through engineering techniques, and the implementation of low-cost production methods to pre-industrial scale trials. FuturEnzyme started in June 2021 and will run until 2025. The program has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 101000327.
Please contact Biosynth for more information.
